The ELISA diagnostic test market size is expected to grow from US$ 1,285.49 million in 2022 to US$ 2,271.23 million by 2030; it is estimated to register a CAGR of 7.37% from 2022 to 2030. Advancements in ELISA-based procedures resulting in increased accuracy are likely to remain key trends in the market.
The rising prevalence of infectious diseases among animals and increasing incidences of human infections are the major factors driving the market growth. According to the Centers for Disease Control and Prevention (CDC) report, enteric diseases linked to animals or environments account for 450,000 cases of illnesses, 5,000 hospitalizations, and 76 deaths among humans in the US alone. Additionally, as per a CDC report published in 2022, every year, 4 in 10 adults in the US have two or more diseases, with 6 in 10 adults having a chronic disease. Moreover, innovative product launches and recent developments in the market are expected to create lucrative opportunities for the ELISA diagnostics test market during 2022-2030.
The rising prevalence of infectious disease among animals and increasing incidences of human infections are the major factors driving the market growth. North America accounts for the major market share closely followed by Europe. The US holds the major market share owing the increasing prevalence of infectious diseases among humans and animals leads to the increased use of ELISA diagnostics test followed by the new product launches by major market players headquartered in the country. Asia Pacific is anticipated to register a significant growth rate owing to the rising animal-associated infection to humans is a standalone factor responsible for the influential market growth in Asia Pacific region. China is one of the major countries where ecology poses a risk for emerging, re-emerging, and novel diseases that could threaten China and the Rest of world owing to the vast population of ~ 1.4 billion and 50% of the world’s livestock. However, The ELISA diagnostic test market in India is expected to flourish during the forecast period owing to increasing government funding, rising healthcare costs, and growing adoption of technologically advanced diagnostic equipment in healthcare organizations.
According to the CDC report published in 2022, every year, 4 in 10 adults in the US have two or more diseases, with 6 in 10 adults having a chronic disease. Among the chronic diseases, over 1.7 million cancer diagnoses are conducted, and nearly 600,000 cancer deaths are recorded every year in the US. Additionally, more than 34 million people in the US (10.5%) have diabetes, with 88 million adults (more than 1 in 3) having prediabetes, resulting in an increase in the risk of suffering from type 2 diabetes. The healthcare expenditure on death and disability due to chronic diseases accounts for US$ 4.1 trillion annually in the US alone.
In humans, ELISA test is used as a biomarker to detect cancer, infectious diseases, autoimmunity, endocrinology diagnosis, immunology & cytokines, cell adhesion molecules (CAMs), and others. ELISA testing helps detect cancer at the early stage of diagnostic processes, offering a better chance for patient survival and getting appropriate treatment initially. Therefore, demand for ELISA testing is high across the world resulting in market growth during the forecast period.
ELISA is one of the most widely used immunoassay tests owing to its various advantages such as flexibility, sensitivity, and easy-to-use features. Additionally, the low cost of ELISA test kit and multifaceted applicability associated with high-throughput testing make it an ideal solution for various research and IVD requirements. With low-cost applicability, product innovations in the test kits increase the demand for human and animal research led to the new product launches in the market. For instance, in June 2022, EUROIMMUN launched two CE marked assays – the Anti-SARS-CoV-2 RBD ChLIA (IgG) and the Anti-SARS-CoV-2 Omicron ELISA (IgG). Both test systems enable the detection of IgG antibodies formed against SARS-CoV-2 and are available to laboratories in countries that accept the CE mark. Additionally, in May 2022, Agdia, Inc. commercialized its assays for detection of Rhizoctonia solani on ELISA and ImmunoStrip platforms.
Key segments that contributed to the derivation of the ELISA diagnostics tests market analysis are adoption, test type, application, and end user.
The geographic scope of the ELISA diagnostics tests market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market owing to the rising infectious diseases among humans, acting as a standalone factor positively influencing the growth of the market. Additionally, technological advancements in ELISA diagnostic kits further enhance the overall market growth during 2022-2030. The US accounts for the major market share owing to the rising incidences of infectious diseases among humans due to high zoonotic disease cases boosting the adoption of ELISA diagnostic tests in the US. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
The regional trends and factors influencing the ELISA Diagnostics Tests Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses ELISA Diagnostics Tests Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,285.49 Million |
| Market Size by 2030 | US$ 2,271.23 Million |
| Global CAGR (2022 - 2030) | 7.37% |
| Historical Data | 2020-2021 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Adoption
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The ELISA Diagnostics Tests Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the ELISA Diagnostics Tests Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The ELISA diagnostics tests market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the ELISA diagnostics tests market are listed below:
The “ELISA Diagnostics Tests Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The expected CAGR of the ELISA diagnostics tests market is 7.64%
The estimated value of the ELISA diagnostics tests market by 2031 is US$ 2.46 Bn.
Advancements in ELISA-Based Procedures results for increased accuracy are the future trends of the ELISA diagnostics tests market
The leading players operating in the ELISA diagnostics tests market includes Bio-Rad Laboratories Inc, Idexx Laboratories Inc, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corp, Innovative Diagnostics , Pictor Ltd, DiaSorin SpA, Elabscience Biotechnology Inc, Bio-Techne Corporation, among others
Rising Infectious Diseases Among Animals and Increasing Incidence of Human Infections are the driving factors impacting the ELISA diagnostics tests market
North America region dominated the ELISA diagnostics tests market in 2023